Framework for predicting alloreactivity in hematopoietic cell transplants

The therapeutic principle of allogeneic hematopoietic cell transplantation, one the most common forms of cancer immunotherapy, is alloreactivity, yet its molecular determinants remain largely unknown. An analytical framework now enables personalized assessment of alloreactivity from whole-exome sequencing of donor–recipient pairs, to help with prognostication of disease relapse and immune-mediated complications.